Published in Blood on March 06, 2012
Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood (2014) 2.00
Myeloma as a model for the process of metastasis: implications for therapy. Blood (2012) 1.36
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget (2014) 1.07
Molecularly targeted therapies in multiple myeloma. Leuk Res Treatment (2014) 1.05
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer J (2014) 1.02
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol (2013) 0.96
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther (2012) 0.96
Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther (2016) 0.93
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep (2015) 0.91
Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol (2015) 0.90
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech (2012) 0.90
Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. Am J Physiol Cell Physiol (2015) 0.89
Promising therapies in multiple myeloma. Blood (2015) 0.89
Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms. Biomark Res (2013) 0.89
Cancer associated fibroblasts and tumor growth: focus on multiple myeloma. Cancers (Basel) (2014) 0.88
Circulating tumor cells in the central and peripheral venous compartment - assessing hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Onco Targets Ther (2014) 0.88
The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene (2015) 0.87
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica (2015) 0.87
Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One (2013) 0.86
Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells. Int J Oncol (2013) 0.86
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials (2015) 0.86
CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood (2014) 0.86
Targeting hypoxic response for cancer therapy. Oncotarget (2016) 0.85
Targeting hypoxia in the leukemia microenvironment. Int J Hematol Oncol (2013) 0.85
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming. Oncotarget (2016) 0.85
A computer vision approach to rare cell in vivo fluorescence flow cytometry. Cytometry A (2013) 0.85
Targeting the Pim kinases in multiple myeloma. Blood Cancer J (2015) 0.84
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) (2015) 0.84
Improved diffuse fluorescence flow cytometer prototype for high sensitivity detection of rare circulating cells in vivo. J Biomed Opt (2013) 0.82
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia (2016) 0.82
The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene (2013) 0.82
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res (2015) 0.81
Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer (2014) 0.80
Design considerations of iron-based nanoclusters for noninvasive tracking of mesenchymal stem cell homing. ACS Nano (2014) 0.80
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J (2016) 0.80
A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. Br J Haematol (2016) 0.80
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood (2016) 0.79
PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol (2015) 0.79
Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells. Front Endocrinol (Lausanne) (2016) 0.79
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. Biomed Res Int (2016) 0.79
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett (2012) 0.78
MIR517C inhibits autophagy and the epithelial-to-mesenchymal (-like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation. Autophagy (2015) 0.78
Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. Oncotarget (2016) 0.77
MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma. Blood Cancer J (2016) 0.77
TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition. Cell Cycle (2016) 0.77
Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia. Cancer Sci (2014) 0.77
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol (2016) 0.76
The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells. Int J Mol Sci (2016) 0.76
Molecular mechanisms of hypoxia in cancer. Clin Transl Imaging (2017) 0.75
Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 0.75
Highly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse. Mol Cells (2016) 0.75
Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma. Haematologica (2016) 0.75
Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy. Cancer Biol Ther (2017) 0.75
HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J Exp Clin Cancer Res (2017) 0.75
Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma. Cancer Sci (2017) 0.75
Metastatic myeloma? Blood (2012) 0.75
Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach. Sci Rep (2015) 0.75
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia. Int J Oncol (2015) 0.75
Network-based analysis of the molecular mechanisms of multiple myeloma and monoclonal gammopathy of undetermined significance. Oncol Lett (2017) 0.75
DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. Neoplasia (2017) 0.75
Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. Transl Oncol (2017) 0.75
EMT and MET-related processes in non-epithelial tumors: importance for disease progression, prognosis and therapeutic opportunities. Mol Oncol (2017) 0.75
Hypoxia and Bone Metastatic Disease. Curr Osteoporos Rep (2017) 0.75
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 9.80
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Hypoxia-inducible factors, stem cells, and cancer. Cell (2007) 5.96
Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene (2005) 5.50
The role of epithelial-mesenchymal transition in cancer pathology. Pathology (2007) 5.16
How do stem cells find their way home? Blood (2005) 5.13
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 4.13
E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev (2009) 3.95
Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci (2009) 3.39
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res (2011) 3.12
The role of hypoxia-induced factors in tumor progression. Oncologist (2004) 2.87
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol (2007) 2.22
E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis (2008) 2.21
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell (1998) 2.00
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2007) 1.99
Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia (2010) 1.76
Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal (2010) 1.68
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 1.66
Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax (2009) 1.57
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther (2002) 1.50
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood (2010) 1.48
Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci U S A (2010) 1.46
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia (2011) 1.39
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood (2009) 1.39
Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer (1997) 1.30
Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev (2003) 1.27
Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol (2006) 1.24
Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin. Cancer Res (2008) 1.19
HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer (2009) 1.17
Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol Rep (2009) 1.15
Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci (2004) 1.10
Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma. Oral Oncol (2010) 1.07
Increased expression of CXCR4 and integrin alphaM in hypoxia-preconditioned cells contributes to improved cell retention and angiogenic potency. J Cell Physiol (2009) 1.06
Feedback regulators of hypoxia-inducible factors and their role in cancer biology. Cell Cycle (2010) 1.03
Hypoxia suppression of Bim and Bmf blocks anoikis and luminal clearing during mammary morphogenesis. Mol Biol Cell (2010) 1.02
Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica (2009) 0.97
Recent advances in tumor hypoxia: tumor progression, molecular mechanisms, and therapeutic implications. Med Sci Monit (2007) 0.96
The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica (2006) 0.96
Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer (2000) 0.96
Increased expression of metastasis-related genes in hypoxic cells sorted from cervical and lymph nodal xenograft tumors. Lab Invest (2009) 0.95
Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer (2008) 0.94
Regulation of XSnail2 expression by Rho GTPases. Dev Dyn (2007) 0.89
Epithelial-mesenchymal transition of rat peritoneal mesothelial cells via Rhoa/Rock pathway. In Vitro Cell Dev Biol Anim (2010) 0.87
Hypoxia-induced abrogation of contact-dependent inhibition of rheumatoid arthritis synovial fibroblast proliferation. J Rheumatol (2009) 0.81
Transcriptional regulation and functional implication of the grass carp CITED1 (gcCITED1) in the negative regulation of HIF-1. Int J Biochem Cell Biol (2010) 0.81
Selective inhibition of BET bromodomains. Nature (2010) 18.79
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63
Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature (2008) 6.61
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60
Chemical imaging of tissue in vivo with video-rate coherent anti-Stokes Raman scattering microscopy. Proc Natl Acad Sci U S A (2005) 5.96
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell (2012) 4.67
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Selective cell targeting with light-absorbing microparticles and nanoparticles. Biophys J (2003) 3.49
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A (2002) 3.28
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science (2003) 3.21
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med (2008) 2.97
Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A (2009) 2.95
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
In vivo flow cytometry: a new method for enumerating circulating cancer cells. Cancer Res (2004) 2.84
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
The requirement for cyclin D function in tumor maintenance. Cancer Cell (2012) 2.49
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47
In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature (2011) 2.44
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem (2008) 2.35
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nat Struct Biol (2003) 2.23
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res (2010) 2.20
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma (2010) 2.20
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging (2003) 2.17
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest (2012) 2.17
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood (2008) 2.10
Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A (2009) 2.08
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood (2010) 2.08
In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood (2010) 2.03
Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci U S A (2002) 2.03
Expert witnesses. Vet Rec (2003) 2.02
Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A (2002) 1.99
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2007) 1.99
Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell (2012) 1.93
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood (2012) 1.91
Pathogenesis of myeloma. Annu Rev Pathol (2011) 1.91
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell (2013) 1.86
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood (2006) 1.83
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res (2003) 1.82
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med (2007) 1.82
Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology (2010) 1.82
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood (2010) 1.79
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood (2011) 1.77